KR102413809B1 - 인간화 항-tf-항원 항체 - Google Patents

인간화 항-tf-항원 항체 Download PDF

Info

Publication number
KR102413809B1
KR102413809B1 KR1020167031646A KR20167031646A KR102413809B1 KR 102413809 B1 KR102413809 B1 KR 102413809B1 KR 1020167031646 A KR1020167031646 A KR 1020167031646A KR 20167031646 A KR20167031646 A KR 20167031646A KR 102413809 B1 KR102413809 B1 KR 102413809B1
Authority
KR
South Korea
Prior art keywords
antibody
jaa
mouse
ser
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167031646A
Other languages
English (en)
Korean (ko)
Other versions
KR20170010356A (ko
Inventor
케이트 리튼 하우스-올슨
줄리아 압둘라
징 잉 엔지
스테펜 티. 코우리
Original Assignee
더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 filed Critical 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕
Publication of KR20170010356A publication Critical patent/KR20170010356A/ko
Application granted granted Critical
Publication of KR102413809B1 publication Critical patent/KR102413809B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020167031646A 2014-04-18 2015-04-20 인간화 항-tf-항원 항체 Active KR102413809B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461981240P 2014-04-18 2014-04-18
US61/981,240 2014-04-18
PCT/US2015/026595 WO2015161311A2 (en) 2014-04-18 2015-04-20 Humanized anti-tf-antigen antibodies

Publications (2)

Publication Number Publication Date
KR20170010356A KR20170010356A (ko) 2017-01-31
KR102413809B1 true KR102413809B1 (ko) 2022-06-28

Family

ID=54324717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167031646A Active KR102413809B1 (ko) 2014-04-18 2015-04-20 인간화 항-tf-항원 항체

Country Status (12)

Country Link
US (1) US11130821B2 (enExample)
EP (2) EP3131581B1 (enExample)
JP (1) JP6740135B2 (enExample)
KR (1) KR102413809B1 (enExample)
CN (1) CN106488774B (enExample)
AU (1) AU2015247358B2 (enExample)
BR (1) BR112016024214B8 (enExample)
CA (1) CA2943681A1 (enExample)
ES (1) ES2843546T3 (enExample)
MX (2) MX378944B (enExample)
RU (1) RU2699717C2 (enExample)
WO (1) WO2015161311A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3609922A2 (en) * 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
MA50195A (fr) * 2017-09-22 2020-07-29 Immunogen Inc Séparation d'anticorps à chaîne triple légère à l'aide d'une chromatographie à échange de cations
CN120586086A (zh) * 2018-03-28 2025-09-05 田边三菱制药株式会社 cMET单克隆结合剂的药物缀合物及其用途
CA3100896C (en) * 2018-05-30 2023-08-29 National Health Research Institutes Anti-abeta antibodies and uses thereof
KR20220032646A (ko) 2018-12-21 2022-03-15 오제 이뮈노테라프틱스 인간화된 항-인간-pd-1 항체
WO2020127369A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
EP3898676A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
KR20220157446A (ko) * 2020-03-23 2022-11-29 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 항-ccr8 항체

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260680A1 (en) 2004-04-16 2005-11-24 Vanderbilt University Methods of diagnosing and treating autoimmune diseases
US20070253950A1 (en) 2006-03-21 2007-11-01 Wyeth Methods for Preventing and Treating Amyloidogenic Diseases
JP2008507584A (ja) 2004-07-26 2008-03-13 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗−ｔｆ−抗原抗体の治療的使用
US20110117086A1 (en) 2009-10-16 2011-05-19 Bioréalités S.A.S. Monoclonal antibodies to progastrin and their uses
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
EP2161031A1 (en) * 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
EP2347769A1 (en) * 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
EP2787081A4 (en) * 2011-11-30 2015-10-07 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX
CN102796144A (zh) * 2012-08-22 2012-11-28 山东大学 Tf抗原及其类似物、和其化学酶法合成方法及其应用
US10023651B2 (en) * 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260680A1 (en) 2004-04-16 2005-11-24 Vanderbilt University Methods of diagnosing and treating autoimmune diseases
JP2008507584A (ja) 2004-07-26 2008-03-13 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗−ｔｆ−抗原抗体の治療的使用
US20070253950A1 (en) 2006-03-21 2007-11-01 Wyeth Methods for Preventing and Treating Amyloidogenic Diseases
US20110117086A1 (en) 2009-10-16 2011-05-19 Bioréalités S.A.S. Monoclonal antibodies to progastrin and their uses
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUTURE ONCOL. (2014) 10(3), 385_399 [DOI/FULL/10.2217/FON.13.209 ]
PNAS, SEPTEMBER 27, 2011, VOL. 108, NO. 39, P.16404_16409

Also Published As

Publication number Publication date
EP3797793A1 (en) 2021-03-31
ES2843546T3 (es) 2021-07-19
CN106488774B (zh) 2019-11-01
WO2015161311A2 (en) 2015-10-22
CN106488774A (zh) 2017-03-08
BR112016024214A2 (pt) 2018-01-23
AU2015247358B2 (en) 2020-02-27
CA2943681A1 (en) 2015-10-22
BR112016024214B8 (pt) 2023-12-26
RU2699717C2 (ru) 2019-09-09
RU2016143552A3 (enExample) 2018-11-14
JP6740135B2 (ja) 2020-08-12
US11130821B2 (en) 2021-09-28
KR20170010356A (ko) 2017-01-31
EP3131581A2 (en) 2017-02-22
AU2015247358A1 (en) 2016-11-10
US20180258182A1 (en) 2018-09-13
MX2016013686A (es) 2017-03-31
EP3131581B1 (en) 2020-09-23
WO2015161311A3 (en) 2015-12-10
BR112016024214B1 (pt) 2023-11-14
MX378944B (es) 2025-03-10
MX2021000439A (es) 2021-03-25
RU2016143552A (ru) 2018-05-21
JP2017518260A (ja) 2017-07-06
EP3131581A4 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
KR102413809B1 (ko) 인간화 항-tf-항원 항체
JP2022137018A (ja) 特異的結合タンパク質およびこれらの使用
CN102112492B (zh) 使用抗gpr49抗体的癌症的诊断和治疗
US10287359B2 (en) Fn14 binding proteins and uses thereof
US11820831B2 (en) Antibody binding to carbonic anhydrase and use thereof
AU2013370171B2 (en) Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
JP2025175994A (ja) がんを処置するための抗ｃｄ３３抗体
AU2005324259A1 (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
US10023651B2 (en) Humanized anti-TF-antigen antibodies
JP2020524527A (ja) ヒト腫瘍幹細胞をターゲティングするモノクローナル抗体及びその使用
HK40042631A (en) Humanized anti-tf-antigen antibodies
HK1233512B (en) Humanized anti-tf-antigen antibodies
JP7788859B2 (ja) がんを処置するための抗ｃｄ３３抗体
JP2024540374A (ja) がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用
HK1157361B (en) Diagnosis and treatment of cancer using anti-gpr49 antibody

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161111

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200309

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210518

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220328

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220623

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220624

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250404

Start annual number: 4

End annual number: 4